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The development of atovaquone (ATQ)-resistant plasmo-
dia strains suggests a need of new drugs for the mitochon-
drial bc1 complex as drug target in protozoa. It was the
aim of the study to establish a model consisting of submi-
tochondrial particles (SMP) from yeast (mimicking the
protozoal drug target) and bovine heart for the screening
of compounds. Saccharomyces cerevisiae wild-type strains
(W303-1A, DBY747) were grown on YPD-media at 30°C
for three days. After harvesting the cells their cell wall was
digested by zymolyase and mitochondria were isolated.
From these organelles SMP where prepared by sonication.
The inhibition of the quinol:cyt c oxidoreductase activity
catalyzed by the mitochondrial bc1 complex of yeast and
bovine heart SMP was measured for a nonspecies-specific
inhibitor stigmatellin and for the anti-malaria drug ATQ.
IC50 values for stigmatellin in both SMP preparations con-
firmed its nonselectivity while ATQ inhibited the yeast
complex activity about 16 times stronger than the activity
of bovine heart SMP. This confirms the functionality of
yeast SMP as model for protozoa. A new lead structure
TMC2O demonstrated an IC50 value of 808 μM and 112μM in yeast and bovine heart SMP, respectively. This sug-
gests that structural adjustments are required to increase
the inhibition in yeast/protozoa. The yeast model in con-
text with yeast strains mimicking mutated protozoa pro-
vides an efficient way to develop drugs for ATQ-resistant
plasmodia strains.
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